The United Kingdom and the United States have secured a landmark trade agreement that will maintain no levies on British medicine shipments entering the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to increase expenditure on medicines through the NHS. This pledge ensures that tariffs on these crucial exports will stay at nothing for a timeframe of the next three years.
This agreement comes after earlier threats to dramatically increase duties on patented drug imports, with figures mentioned as high as 100%.
"This deal between the UK bolsters the worldwide climate for new treatments and establishes long-overdue fairness to transatlantic pharmaceutical trade," a statement declared.
Commercial Significance
Medicines represent one of the the United Kingdom's largest export categories to the United States, which is by far the primary market for major companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period leading up to September, the UK sold medicines valued at over eleven billion pounds to the US. This value accounted for a significant portion of total UK exports in that period.
"This guarantee secures work, increases investment and facilitates the UK to become a worldwide center for biotech and pharma," a government official stated.
Specific NHS Changes
The pact involves several specific commitments from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to raise overall public funding on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates exceeded twenty percent.
Industry Background
This agreement comes amid a long-running tension between the drug companies and the British authorities over medicine costs and NHS adoption.
These tensions were intensified by arguments that US patients were paying a premium for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while substantial investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the last ten years.
